[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrotic-interstitial-lungs-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrotic-interstitial-lungs-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100628805","study-on-the-efficacy-of-quercetin-intake-in-patients-with-fibrotic-interstitial-lung-diseases-100628805",false,"NCT07466420","Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.","Study on the Efficacy of Quercetin Intake in Patients With Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis. A Two-arm, Prospective Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.\n* The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care.\n\nExclusion Criteria:\n\n* Subjects with a result of FeNO\\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present.\n* Patients who do not initiate quercetin within the first week after their baseline visit.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. Ongoing research aims to identify reliable biomarkers and develop targeted treatments to enhance patient outcomes.\n\nThis randomized controlled trial will examine the effects of quercetin supplementation (500 mg\u002Fday for two 12-week cycles, with one 8-week washout periods) on telomere length, senescence-associated secretory phenotype (SASP) factors, and lung function in patients with IPF and F-ILDs. A total of 100 patients will be recruited, with half receiving quercetin (despite their standard of care therapy) and the other half receiving standard care (SOC). Primary outcomes will include changes in telomere length, SASP protein levels (IL-6, MMPs), fractional exhaled nitric oxide (FeNO), spirometry (FVC decline), and oscillometry measurements. Additionally, quality of life will be assessed using the L-IPF Questionnaire.\n\nThis study aims to explore quercetin's potential to reduce fibrosis, decrease inflammation, and improve lung function in F-ILDs, offering new insights into potential novel strategies for F-ILD management.",[26,27,28],"Fibrotic Interstitial Lungs Diseases","Idiopathic Pulmonary Fibrosis (IPF)","Progressive Pulmonary Fibrosis","RECRUITING","2026-03-09",{"date":32,"type":33},"2026-03-12","ACTUAL",{"date":35,"type":33},"2026-01-26",{"date":37,"type":20},"2029-01-31",{"name":39,"class":40},"Katerina M. Antoniou","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100530128","physical-activity-and-fibrosing-interstitial-lung-disease-100530128","NCT06182748","Physical Activity and Fibrosing Interstitial Lung Disease","AP-PID","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Fibrosing PID with fibrosis score \\> 10% of lung volume on chest CT scan\n* Be able to attend physical reconditioning 3 times a week\n* Be affiliated to a health insurance scheme\n* Sign informed consent form\n\nExclusion Criteria:\n\n* Any contraindication to physical activity (hereafter, after Dany-Michel Marcadeta, Bruno Pavy et al. Recommendations of the French Society of Cardiology for stress tests 2018)\n* Be unable to perform exercise on an ergocycle or treadmill\n* Be unable to perform a stress test, particularly for people on long-term oxygen therapy rest oxygen therapy at home\n* IRS during an exacerbation\n* Change in treatment \\\u003C 3 months\n* Sarcoidosis\n* Connectivitis\n* Pregnancy in progress\n* Participation in a therapeutic intervention study\n* Patient under guardianship\n* Person subject to a legal protection measure\n* Patient on state medical aid",{"count":50,"type":20},60,[23],"Fibrotic interstitial lungs diseases (ILD) are a group of chronic and rare diseases characterized by an altered blood oxygenation in the lung, leading to dyspnea and physical limitation. Physical training is efficient to fight vicious circle of physical deconditioning observed in ILD. Eccentric cycling is an interesting modality of endurance training, allowing better exercise tolerance and adherence while developing cardiorespiratory function. Feasibility and efficacity of eccentric cycling were shown in chronic obstructive pulmonary disease but never in ILD. The primary aim of our work is to compare concentric and eccentric cycling training on physical capacities in ILD. Moreover, we will study the effects of training on the different steps of oxygen transport at exercise, from the lung to the muscles through the blood transport. Our second goal is then to characterize the physiological mechanisms underlying the benefits of exercising in ILD patients. Evaluations will be led during one year to study the long-term effects of training",[26],"2024-10-18",{"date":56,"type":33},"2024-10-21",{"date":58,"type":33},"2023-11-30",{"date":60,"type":20},"2026-01-30",{"name":62,"class":40},"Assistance Publique - Hôpitaux de Paris"]